Skip to main content
SpringerLink
Log in

Counting the costs of continued smoking after CVE

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The study was sponsored by Pfizer SLU.

Reference

  • Sicras-Mainar A, et al. Cost and clinical consequences of smoking cessation in outpatients after cardiovascular disease: a retrospective cohort study. ClinicoEconomics and Outcomes Research : 19 Aug 2013. Available from: URL: http://dx.doi.org/10.2147/CEOR.S43256

    PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Counting the costs of continued smoking after CVE. PharmacoEcon Outcomes News 686, 7 (2013). https://doi.org/10.1007/s40274-013-0683-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-013-0683-0

Search

Navigation